DALLAS--(BUSINESS WIRE)--Impossible Dream Machine Partners with Parkland Center for Clinical Innovation (PCCI). ...

排版丨水成文 可转座元件 （ Transposable element， TE） 占据了近一半的基因组，并推动了发育创新，然而， 长末端重复序列 （Long Terminal Repeat，LTR） 是某些 可转座元件 两端的 DNA 重复序列，它们对元件的复制、整合和基因 表达调控发挥着关键作用。然而，我们对于 LTR 沉默的机制仍不完全清楚。 2025 年 10 月 29 日，同济大学 高绍荣 院士、 高亚威 教授、 王译萱 教授，北京大学 刘君 教授团队合作 （ 朱学昊、常展赫、肖维德为论文共同第一作者 ） ，在 Cell Stem Cell 期刊 发表了题： N6-methyladenosine on L1PA Governs the Trans-silencing of LTRs and Restrains totipotency in Naïve Human Embryonic Stem Cells 的研究论文。 编辑丨王多鱼 METTL3 缺失可使 naïve 人类胚胎干细胞 （hESC） 获得全能性并激活 8-细胞转录组； L1PA 上的 m6A 修饰的去除激活了 8-细胞 LTR，并诱导 n ...

Core Insights - Cuprina Holdings has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions to explore the integration of its medical waste recycling technology into SBS's waste management facility in Singapore [1][2][3] Company Overview - Cuprina Holdings is a biomedical company focused on developing and marketing products for chronic wounds, infertility, and cosmeceuticals [1][6] - Singapore Biowaste Solutions is recognized as Singapore's most advanced provider for biomedical waste disposal and management [7] Collaboration Details - The collaboration aims to reduce reliance on incineration and landfilling, enhance recycling efficiency, and unlock new revenue streams from recycled materials [2][5] - Cuprina will provide technical expertise, training, and support for a feasibility study and pilot program at SBS's facility [3][4] - SBS will contribute operational data, facility access, and regulatory support to ensure compliance with Singapore's environmental standards [4] Technology and Innovation - Cuprina's technology involves a high-temperature steam process known as autoclaving, which sterilizes, decontaminates, and recycles plastic-based medical waste into high-value resins [3] - This technology has been developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF) [3] Future Prospects - The companies plan to develop revenue-sharing models for the integrated process and explore expansion opportunities across Southeast Asia [5] - Cuprina's CEO expressed optimism that the integrated recycling technology could secure necessary regulatory approvals and commence operations by the end of 2026 [5]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Bio-Rad Laboratories, with a focus on how actual results compare to estimates, which could significantly impact stock price [1][2]. Earnings Expectations - Bio-Rad is expected to report quarterly earnings of $2.30 per share, reflecting a year-over-year increase of 14.4%. Revenues are projected to be $651.42 million, up 0.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate for Bio-Rad, resulting in an Earnings ESP of 0%. The stock currently holds a Zacks Rank of 4, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, Bio-Rad exceeded expectations by posting earnings of $2.61 per share against an expected $1.93, achieving a surprise of 35.23%. Over the last four quarters, the company has beaten consensus EPS estimates three times [13][14]. Conclusion - While Bio-Rad does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Core Insights - Alexandria Real Estate Equities, Inc. has been awarded the 2025 Charles A. Sanders, MD, Partnership Award by the Foundation for the National Institutes of Health (FNIH) for its leadership in a public-private partnership aimed at advancing precision medicine for depression [1][2] - The initiative, known as Multi-Level Assessment & Phenotyping in Depression (MAP-D), seeks to develop a comprehensive framework for treating major depressive disorder, which affects over 21 million adults in the U.S. annually [2][3] - The MAP-D program aims to create a large depression research dataset, validate new measurement methods, and identify biomarkers to guide treatment decisions [3][4] Company Overview - Alexandria Real Estate Equities, Inc. is a leading life science real estate investment trust (REIT) with a market capitalization of $25.7 billion as of June 30, 2025, and operates in key life science innovation clusters across North America [5][6] - The company specializes in developing collaborative Megacampus ecosystems and has a significant asset base, including 39.7 million rentable square feet (RSF) of operating properties and 4.4 million RSF of properties under construction [5][6] - Alexandria also provides strategic capital to transformative life science companies through its venture capital platform, enhancing its role in the life science ecosystem [6]

Group 1 - Standard BioTools Inc. will publish its third quarter 2025 financial results on November 4, 2025, after U.S. market close [1] - The company is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [2] - Standard BioTools utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease [2] Group 2 - The company collaborates with various sectors including academic, government, pharmaceutical, and biotechnology laboratories globally [2] - Focus areas for Standard BioTools include translational and clinical research, particularly in oncology, immunology, and immunotherapy [2]

Company Overview - Leidos Holdings, Inc. (LDOS) is a Virginia-based technology company specializing in defense, aviation, information technology, and biomedical research with a market cap of $23.9 billion and approximately 47,000 employees [1] - The company operates across four primary divisions: National Security & Digital, Health & Civil, Commercial & International, and Defense Systems [1] Earnings Expectations - Analysts expect LDOS to report a profit of $2.62 per share on a diluted basis for the fiscal third quarter of 2025, which represents a decline of 10.6% from $2.93 per share in the same quarter last year [2] - For the full fiscal year, analysts anticipate an EPS of $11.41, reflecting an increase of 11.8% from $10.21 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, LDOS stock has increased by 9.7%, which is lower than the S&P 500 Index's 13.5% gains and the Technology Select Sector SPDR Fund's 24% gains during the same period [4] - Following the release of strong Q2 results on August 5, Leidos Holdings' shares surged by 7.5%, with revenue rising 2.9% year over year to $4.3 billion, exceeding expectations [5] Analyst Ratings - The consensus opinion on LDOS stock is reasonably bullish, with a "Moderate Buy" rating overall; out of 16 analysts, ten recommend a "Strong Buy," one suggests "Moderate Buy," and five give a "Hold" [6] - The average analyst price target for LDOS is $196.28, indicating a potential upside of 6.4% from current levels [6]

Core Viewpoint - Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons, leading to dopamine depletion and motor symptoms. Current treatments alleviate symptoms but do not halt neuronal loss [2][5]. Group 1: Research and Development - PD has long been considered a suitable candidate for cell replacement therapy due to its clear pathological features, specifically the loss of certain dopaminergic neuron populations [5]. - A recent study published in the journal Cell reported a Phase 1/2a clinical trial of human embryonic stem cell (hESC)-derived dopamine progenitors (A9-DPC) showing good safety and effective improvement in motor symptoms for PD patients [3][12]. - The development of hPSC, including hESC and induced pluripotent stem cells (iPSC), has provided scalable sources for generating dopamine progenitor cells, enabling large-scale production of high-purity dopamine progenitor cells [5][6]. Group 2: Clinical Trial Findings - The Phase 1/2a trial involved 12 patients with severe PD, where A9-DPC was transplanted into the bilateral shell nucleus under an immunosuppressive regimen. The low-dose group received 3.15 million cells, while the high-dose group received 6.3 million cells [8][9]. - Results indicated excellent safety with no dose-limiting toxicities or transplant-related adverse events. Motor function improved significantly, with the high-dose group showing greater improvement [8][9]. - PET imaging confirmed increased dopamine uptake in the bilateral posterior shell nucleus, particularly in the high-dose group, indicating cell survival post-transplant [9][12]. Group 3: Conclusion and Implications - The study concluded that hESC-derived dopamine progenitor cells (A9-DPC) transplantation into the bilateral shell nucleus demonstrates good safety and effectively improves motor symptoms in PD patients, exhibiting dose-dependent efficacy [12].

Core Points - Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals for health and beauty [1][6] - The company will present at the Skyline Signature Series™ on October 8, 2025, at 11:00 AM ET, allowing investors to engage in real-time Q&A [1][2][3] Event Details - Event Name: Skyline Signature Series™ [3] - Date: October 8, 2025 [3] - Time: 11:00 AM ET [3] - Registration Link: https://us02web.zoom.us/webinar/register/WN_wWWf2nr8QZmKgzx7IaKrXA/registration [3] About Skyline Corporate Communications Group - Skyline Corporate Communications Group, LLC provides investor relations services and ensures a high-quality audience for public companies through careful vetting [4][5] - The firm has experience in strategic messaging and investor communications for public corporations across various industries [5]

Core Insights - The article discusses the revolutionary impact of spatial transcriptomics technology on biomedical research, enabling analysis of gene activity in cells and tissues with spatial resolution [3][4][5] Group 1: Technology Overview - Spatial transcriptomics technology can be categorized into two main types: spatial capture/labeling techniques and image-based techniques, each with its own advantages and limitations [3] - Existing methods face a dilemma where spatial resolution and transcriptome coverage cannot be achieved simultaneously, leading to a compromise in data quality [3] Group 2: RAEFISH Method - The RAEFISH method, developed by a team from Yale University, offers a sequencing-free approach that combines whole-genome coverage (22,000 mouse genes and 23,000 human genes) with single-molecule resolution [4][5] - This method allows for precise localization of individual RNA molecules within cells, addressing the limitations of previous spatial transcriptomics technologies [4][5] Group 3: Applications and Implications - RAEFISH enables high-resolution spatial analysis of gene transcripts, revealing subcellular localization, cell type specificity, and intercellular interaction patterns [5][7] - The technology represents a significant advancement in spatial transcriptomics, providing a powerful tool for various fields such as developmental biology, neuroscience, tumor microenvironment research, and drug discovery [7]